Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company, which is engaged in the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. It manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. It has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment.
äŒæ¥ã³ãŒãCUPR
äŒç€ŸåCuprina Holdings (Cayman) Ltd
äžå Žæ¥Apr 10, 2025
æé«çµå¶è²¬ä»»è
ãCEOãMr. Yong Qi (David) Quek
åŸæ¥å¡æ°14
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Apr 10
æ¬ç€Ÿæåšå°Block 1090
éœåž
蚌åžååŒæNASDAQ Capital Market Consolidated
åœSingapore
éµäŸ¿çªå·169201
é»è©±çªå·6585127275
ãŠã§ããµã€ãhttps://cuprina.com/
äŒæ¥ã³ãŒãCUPR
äžå Žæ¥Apr 10, 2025
æé«çµå¶è²¬ä»»è
ãCEOãMr. Yong Qi (David) Quek
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã